Acousia Therapeutics GmbH, founded in 2012, is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing proprietary small molecule drug candidates for enhancing and protecting hearing in patients with hearing loss.

ASpherecousia is developing drugs for local and systemic application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat patients with age-related hearing loss.